Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia

Leukemia Research

Volumn 31, Issue 8, 2007, Pages 1045-1051

  Hidaka, Hirokazu ^a   Yagasaki, Hiroshi ^a   Takahashi, Yoshiyuki ^a   Hama, Asahito ^a   Nishio, Nobuhiro ^a   Tanaka, Makito ^a   Yoshida, Nao ^a   Villalobos, Itzel Bustos ^a   Wang, Yue ^a   Xu, YinYan ^a   Horibe, Keizo ^b   Chen, Sen ^a   Kadomatsu, Kenji ^a   Kojima, Seiji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Acute leukemia; Children; Midkine; Minimal residual disease; Prognostic factor; Real time PCR; WT1

Indexed keywords

MIDKINE; WT1 PROTEIN; MDK PROTEIN, HUMAN; MESSENGER RNA; NERVE GROWTH FACTOR; RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ACUTE LYMPHOCYTIC LEUKEMIA; B CELL LEUKEMIA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MYELOID LEUKEMIA; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; BLOTTING, WESTERN; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MYELOID; MALE; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 34249888766     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.09.005     Document Type: Article

References (34)

1. Kadomatsu K., Tomomura M., and Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stage of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 151 (1998) 1312-1318
2. Kaname T., Kuwano A., Murano I., Uehara K., Muramatsu T., and Kajii T. Midkine gene (MDK), a gene for prenatal differentiation and neuroregulation, maps to band 11p11.2 by fluorescence in situ hybridisation. Genomics 17 (1993) 514-515
3. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 132 (2002) 359-371
4. Kadomatsu K., and Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 204 (2004) 127-143
5. Matsubara S., Take M., Pedraza C., and Muramatsu T. Mapping and characterization of a retinoic acid-responsive enhancer of midkine, a novel heparin binding growth/differentiation factor with neurotrophic activity. J Biochem 115 (1994) 1088-1096
6. Kojima S., Muramatsu H., Amanuma H., and Muramatsu T. Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 270 (1995) 9590-9596
7. Qi M., Ikematsu S., Ichihara-Tanaka K., Sakuma S., Muramatsu T., and Kadomatsu K. Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of bcl-2 expression by midkine. J Biochem 127 (2000) 269-277
8. Muramatsu H., and Muramatsu T. Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem Biophys Res Commun 177 (1991) 652-658
9. Kadomatsu K., Hagihara M., Akhter S., Fan Q.W., Muramatsu H., and Muramatsu T. Midkine induces the transformation of NIH3T3 cells. Br J Cancer 75 (1997) 354-359
10. Choudhuri R., Zhang H.T., Donnini S., Ziche M., and Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57 (1997) 1814-1819
11. Sato W., Kadomatsu K., Yuzawa Y., Muramatsu H., Hotta N., Matsuo S., et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol 167 (2001) 3463-3469
12. Aridome K., Tsutsui J., Takao S., Kadomatsu K., Ozawa M., Aikou T., et al. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 86 (1995) 655-661
13. Garver Jr. R.I., Chan C.S., and Milner P.G. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol 9 (1993) 463-466
14. Garver Jr. R.I., Radford D.M., Donis-Keller H., Wick M.R., and Milner P.G. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74 (1994) 1584-1590
15. O'Brien T., Cranston D., Fuggele S., Bicknell R., and Harris A.L. The angiogeneic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 56 (1996) 2515-2518
16. Nakagawara A., Milbrandt J., Muramatsu T., Deuel T.F., Zhao H., Cnaan A., et al. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 55 (1995) 1792-1797
17. Tsutsui J., Kadomatsu K., Matsubara S., Nakagawara A., Hamanoue M., Takao S., et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 53 (1993) 1281-1285
18. Muramatsu H., Song X.J., Koide N., Hada H., Tsuji T., Kadomatsu K., et al. Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas. J Biochem 119 (1996) 1171-1175
19. Ikematsu S., Yano A., Aridome K., Mikuchi M., Kumai H., Nagano H., et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 83 (2000) 701-706
20. Kadomatsu K., Huang R.P., Suganuma T., Murata F., and Muramatsu T. A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in spatially and temporally controlled manner during mouse embryogenesis. J Cell Biol 110 (1990) 607-616
21. Adachi Y., Reynolds P.N., Yamamoto M., Wang M., Takayama K., Matsubara S., et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 61 (2001) 7882-7888
22. Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., et al. WT1 as a new prognostic factor and a new marker the detection of minimal residual disease in acute leukemia. Blood 84 (1994) 3071-3079
23. Menssen H.D., Siehl J.M., and Thiel E. Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol 76 (2002) 103-109
24. Baird P.N., and Simmons P.J. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 25 (1997) 312-320
25. + hematopoietic progenitors during fetal development and early clonogenic growth. Blood 89 (1997) 3486-3496
26. + progenitors. Blood 90 (1997) 4230-4238
27. + haematopoietic progenitor cells express the Wilms' tumor gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 116 (2002) 409-420
28. Takei Y., Kadomatsu K., Matsuo S., Itoh H., Nakazawa K., Kubota S., et al. Antisense oligodeoxynucleotide targeted to midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61 (2001) 8486-8491
29. Boubkikova L., Kalinova M., Ryan J., Quinn F., O'Marcaigh A., Smith O., et al. Wilms' tumor gene1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20 (2006) 254-263
30. Adachi Y., Matsubara S., Pedraza C., Ozawa M., Tsutsui J., Takamatsu H., et al. Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1). Oncogene 13 (1996) 2197-2203
31. Willman C.L., Kang H., Potter J.W., Harvey R.C., Atlas S.R., Bedrick Ed., et al. A gene expression classifier for improved risk classification and outcome prediction in pediatric acute lymphoblastic leukemia (ALL). Blood 106 (2005) 225a
32. Schrappe M., Reiter A., Zimmermann M., Harbott J., Ludwig W.D., Henze G., et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group form 1981 to 1995. Leukemia 14 (2000) 2205-2222
33. Campana D. Determination of minimal residual disease in leukemia patients. Br J Haematol 121 (2003) 823-838
34. Foroni L., Harrison C.J., Hoffbrand A.V., and Potter M.N. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukemia by molecular analysis. Br J Haematol 105 (1999) 7-24